Cosmo Pharmaceuticals

Inversion rule change prompts AbbVie to halt Shire takeover

Thursday, October 16, 2014

In what could have been a major pharmaceutical acquisition and one of the biggest tax inversion deals, Chicago-based AbbVie has recommended its shareholders vote against its proposed $54 billion takeover of Shire, a Dublin-headquartered pharmaceutical company specializing in medications to treat attention deficit disorder and rare diseases

[Read More]